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Edited by Gerrit van MeerAbstract Mitochondrial fatty acid synthesis is catalyzed by a
dissociated fatty acid synthase similar to those of plant plastids
and bacteria. The crystal structure of a mitochondrial b-
ketoacyl-[acyl carrier protein] synthase (mtKAS), namely that
from Arabidopsis thaliana, has been determined for the ﬁrst
time. This enzyme accomplishes the vital condensation steps in
constructing fatty acid carbon skeletons. The product proﬁle of
mtKAS is unusual in that C8 and C1416 fatty acyl chains
predominate. An enzyme architecture that likely is the basis for
the observed bimodal proﬁle of mtKAS products can be derived
from the shape of the acyl binding pocket.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Fatty acid synthase (FAS) complexes consist of the small acyl
carrier protein (ACP) cofactor and a set of enzymatic activities
either gathered on very large multifunctional polypeptides
(type I) or organized from discrete enzymes (type II). In a re-
iterative manner, short carbon units activated by ACP or co-
enzyme A are joined together by FAS and then prepared for the
next round of elongation. For many years, the type I and II
FAS systems were believed to be mutually exclusive, with type I
occurring in the cytoplasm of animals and fungi [1], and with a
few exceptions, type II in bacteria [2] and plastids [3]. Seeking
an explanation for the presence of ACP in the mitochondria of
Neurospora crassa [4], however, led to the identiﬁcation of
nuclear genes potentially encoding other components of type II
FAS systems for the mitochondria of fungi, plants and animals
[5–10]. Some of the products of these genes have been shown to
carry mitochondrial targeting signals and have the requisiteq The coordinates and structure factors have been deposited in the Pro-
tein Data Bank at EBI (http://www.ebi.ac.uk/msd) as entry 1W0I.
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doi:10.1016/j.febslet.2004.10.007activities to function in fatty acid synthesis. Combining all
possible observations leads to the inference that a mitochon-
drial FAS II system exists in all eukaryotes.
FAS is an interesting target for both cytostatica and antibi-
otics. Fatty acid synthesis is substantially elevated in tumor cells
[11] and FAS inhibitors, such as the natural antibiotic cerulenin,
impede tumor growth and induce apoptosis [12]. The diﬀeren-
tial sensitivity of FAS complexes to antibiotics makes FAS a
favorable target for the development of antibiotics [13]. Ceru-
lenin inhibits the condensing enzyme, b-ketoacyl-ACP synthase
(KAS) component of FAS, performing the three step Claisen
condensation reaction. Speciﬁcally, cerulen-in binds covalently
to the active site cysteine, occupying the acyl binding pocket
[14,15] and thereby prohibiting binding of the acyl substrate.
Among the best characterized of the mitochondrial type II
FAS components is theKAS enzyme fromArabidopsis thaliana,
mtKAS [10]. This enzyme, as KAS I of Escherichia coli, is a
promiscuous condensing enzyme accepting C4–14 acyl sub-
strates. The enzymes diﬀer in thatmtKASalso extends saturated
C2 and C16 acyl chains [10], while KAS I elongates unsaturated
C10:1–14:1acyl chains [16].E. coliKASII is similar toKASI except
for selecting C16:1 rather than C10:1-C14:1 acyl chains [16]. A
second attribute distinguishing mtKAS from other KAS en-
zymes is the unusual product proﬁle having two maxima, one
with C8 and one with C14–C18 acyl chains [10,17]. While the
former are precursors for lipoic acid [17], the function of the
longer acyl chains remains to be demonstrated. Their partici-
pation in phospholipid remodeling has been proposed [18].
Crystal structures determined for theE. coliKASI [19] and for
KAS II from E. coli [20], Streptococcus pneumoniae [21] and
Synechocystis sp. [22] have not clariﬁed the structural basis for
substrate preferences of these enzymes. The current work pre-
sents the ﬁrst successful puriﬁcation of a KAS enzyme from a
eukaryotic type II FAS, namely theA. thalianamtKAS, leading
to the determination of its molecular structure. Superimposing
the cerulenin complexed structures ofE. coliKAS I and II on the
acylbindingpocketofmtKASrevealsnotonly the likelybasis for
the bimodal product distribution, but also a factor contributing
to the extreme sensitivity of mtKAS to the inhibitor cerulenin.2. Materials and methods
2.1. Cloning, expression, and puriﬁcation of recombinant protein
DNA encoding a truncated version of A. thaliana cDNA AB073746
encoding mtKAS was recloned from pKK233-2 [10] into pQE30
(Qiagen). The mtKASD20 sequence, lacking the ﬁrst 20 codons of theblished by Elsevier B.V. All rights reserved.
Table 1
Data collection and reﬁnement statistics
Native 1 Native 2 Native 3 Native 4 Merged data
Data collection
Beam line DESY/X13 DESY/X13 DESY/X13 ESRF/BM14
Wavelength (A) 0.802 0.802 0.802 0.984
Cell dimensions a ¼ 71:8 A a ¼ 71:8 A a ¼ 71:8 A a ¼ 72:2 A
b ¼ 92:8 A b ¼ 92:8 A b ¼ 92:7 A b ¼ 93:2 A
c ¼ 73:4 A c ¼ 73:5 A c ¼ 73:5 A c ¼ 74:0 A
b ¼ 106:4 b ¼ 106:4 b ¼ 106:4 b ¼ 106:4
Resolution range (last shell) (A) 20.1–2.4
(2.5–2.4)
20.7–2.5
(2.6–2.5)
20.9–3.0
(3.2–3.0)
36.5–2.1
(2.2–2.1)
23.6–2.1
(2.2–2.1)
Number of unique reﬂection 13 076 7468 2065 31 170 42 636
Rmerge (last shell)a 0.133 (0.360) 0.130 (0.351) 0.199 (0.466) 0.098 (0.259) 0.145 (0.262)
Multiplicity 1.7 1.7 1.5 1.9 3.5
Completeness (%) 61.0 49.0 30.1 89.0 95.4
Average I/r 5.3 5.2 3.6 3.4 4.4
Reﬁnement statistics
Number of reﬂections 52211
Resolution range (last shell) (A) 23.7–2.10
(2.19–2.10)
Number of non-hydrogen protein atoms 6430
Number of atoms in ions 17
Number of water molecules 565
R-factorb 17.8
Rfreeb 22.1
Cross-validated estimated coordinate error using r (A)c 0.2
rmsd
Bond length (A)c 0.006
Bond angle ()c 1.2
Dihedral angle ()c 22.8
Improper torsion ()c 0.8
Average B
Protein (A2) 12.4
Water (A2) 23.3
Ions (A2) 31.7
rmsd between ncs-related subunits (A) 0.3
aRmerge ¼
P
hkl
P
i jIiðhklÞ  hIiðhklÞij=
P
hkl
P
i IiðhklÞ.
bR-factor ¼Phkl kFobsj  jFcalck=
P
hkl jFobsj, with Rfree calculated using 5% of the reﬂections held aside during the reﬁnement process.
c Calculated in CNS [28].
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GGTGGTGGTGGATCCATCTCTACTTCTTCTTC-30 and 30 PstI
50-GAAGCTTGGCTGCAGTTAGATAGATAG-30, and subcloned
into pQE30 (Qiagen). The resulting pQEmtKAS vector, encoding an
MRGSHHHHHHG N-terminal sequence preceding that of
mtKASD20, was transformed using standard techniques into
C41(DE3) cells previously transformed with pREP4 (Qiagen).
Expressionwas carried out as previously described [23], excepting that
induction was optimized by overnight incubation at 20 C to avoid in-
clusion of body formation. After cell disruption by lysozyme treatment,
followed by endonuclease treatment and centrifugation, the supernatant
was subject to Ni2þ aﬃnity chromatography on a 5 mL HiTrap che-
latingHP column (all columns were fromAmershamBiosciences). After
buﬀer exchange [to 30 mM Tris–HCl (tris[hydroxymethyl]aminometh-
ane hydrochloride), 2 mMEDTA, and 1mMDTT, pH 8.0] on aHiPrep
26/10 desalting column, the protein was further puriﬁed by ion exchange
chromatography on a MonoQ HR10/10 column. The puriﬁed enzyme
was buﬀer exchanged on a HiPrep 26/10 desalting column into 30 mM
Tris–HCl, 2 mM EDTA, and 1 mMDTT (pH 8.0) and concentrated to
16.3 mg/mL based on a theoretical A1 mg=mL280 ¼ 0:467.. This procedure
yielded a total of 2 mg mtKAS from 1 L cell culture.Fig. 1. Ribbon representation of A. thaliana mtKAS. Active site
Cys209, His350 and His389 are included. One subunit is colored ac-
cording to secondary structural elements, while in the other subunit the
core ababa structure is white and the cap region is dark gray. The
purple spheres represent cations inferred to be Kþ.2.2. Crystallization and data collection
Hanging drop experiments using equal volumes of mother liquor
and protein solution equilibrated against 1.6 M (NH4)2SO4 and 0.1 M
MES (2-[N-morpholino]propanesulfonic acid)-buﬀer at pH 6.0 lead to
elongated plate shaped crystals with average dimensions of 0.4
172 J.G. Olsen et al. / FEBS Letters 577 (2004) 170–174mm 0.05 mm 0.01 mm. The crystals were cooled in N2ðlÞ after
transfer to a cryo-protectant consisting of 1.6 M (NH4)2SO4, 0.1 M
MES-buﬀer and 25% (v/v) glycerol at pH 6.0. Exposure of the crystals
to X-ray radiation resulted in severe crystal damage and a full data set
from the exposure of a single crystal was unobtainable. Consequently,
the data from four crystals were scaled and merged. Data from
one crystal were collected at ESRF beam line BM14 and from three
other crystals at DESY beam line X11 (Table 1). The space group of
the crystals is P21 with a ¼ 71:8 A, b ¼ 92:8 A, c ¼ 73:4 A, and
b ¼ 106:4, making room for one mtKAS dimer in the asymmetric
unit.
2.3. Phasing, model building and reﬁnement
Escherichia coli KAS I, pdb code 1EK4 [24] was used as search
model for the initial phase estimation by molecular replacement [25].
Phases were improved by automated model building in ARP/wARP
[26], and complete protein chains constructed after model building in O
[27] and model reﬁnement in CNS [28]. After inclusion of water mol-
ecules, ﬁve of them appeared more likely to be ions because of very low
B-factors, the shape of the electron density and the number and or-
ganization of coordinating atoms. Three sulfate ions, two in the A
subunit and one in B, were included at the molecular surface, all with
salt bridges to arginine residues. A Kþ ion in each subunit was in-
cluded in the intramolecular cation site previously observed in Strep-
tococcus pneumoniae KAS II [21]. The identiﬁcation of the cation in
mtKAS is based on model reﬁnement trials including NHþ4
(hBfactori ¼ 1:7 A2), Naþ (hBfactori ¼ 14:6 A2), Kþ (hBfactori ¼ 22:7 A2),
Ca2þ (hBfactori ¼ 23:0 A2) or Mg2þ (hBfactori ¼ 13:3 A2), assuming
100% occupancy of the site. The average cation ligand distance of 2.8
A suggests an NHþ4 or K
þ ion [29]. The non-realistic low B-factor of
the NHþ4 model (reset to 1.7 A
2 after having dropped below the B-
factor limit in the reﬁnement procedure), however, argues for the more
electron dense Kþ, possibly partly occupied. Alternating occupancy
and Bfactor reﬁnement of the K
þ model gave converged occupancies of
0.5/0.6 with corresponding B-factors of 7.1 A2/9.3 A2. The side chain
of Thr 354 was reﬁned in two alternate conformations.3. Results and discussion
3.1. Architecture of mtKAS
Two subunits of mtKAS are associated into a dimer in the
asymmetric unit, with each subunit contributing to the dimer
interface with an area of 3466 A2 [30]. This is 350–1200 A2
larger than the interfaces formed by other KAS I, II and III
dimers. As in KAS I and KAS II structures, each subunit is
organized in two entities, a large ababa sandwich carrying the
active site residues and an a-helical cap above the active site
(Fig. 1). The structure of mtKAS has two major structural
extensions compared to KAS I and KAS II enzymes. These areFig. 2. Superposition of mtKAS (dark gray) and the high resolution struct
mtKAS structure with the largest deviations from KAS II structures are coloan extra a-helical segment in the cap region contributing to the
dimer interface (mtKAS residues 67–83) and a solvent exposed
loop in the ababa domain (mtKAS residues 98–105) (Fig. 2).
In addition, a minor extension is found in the 374–375 region.
The dimer formation observed in all KAS enzymes plays a role
for the deﬁnition of the fatty acyl binding pocket. With respect
to overall size, position and hydrophobic nature, the mtKAS
pocket resembles the KAS I and II pockets. At a more detailed
level, several observations imply that mtKAS is closely related
to KAS II. For example, the active site water structure of
mtKAS resembles that observed in the KAS II enzymes from
T. thermophilus (pdb code: 1j3n) and Synechocystis sp. [20], in
particular no short hydrogen bonds are observed from active
site residue His350 ND1.
3.2. Substrate binding implications
Only hydrophobic residues line the mtKAS acyl pocket
(Fig. 3A). Analogous residues in all other deduced mtKAS
sequences [NCBI Accession Codes: CAA21898, P39525,
AAB81078, BAB30490, BAA91286, CG12170-PA,
XM_312104, AK116556, CE30752, F10G8.9(Z80216) and
CBP01094] are also hydrophobic. By comparison, the bottom
of this pocket in E. coli includes Glu200 and Gln113 in KAS I
and Thr137 in KAS II (Figs. 3B and C, respectively).
Cerulenin inhibits KAS by binding covalently to the active
site cysteine. The resulting complexes, for example those with
E. coli KAS I and II [14,15], are products of a nucleophilic
addition to the cerulenin epoxide, and not of a nucleophilic
substitution characterizing the formation of KAS:fatty acyl
complexes. Furthermore, the leaving group of the natural
substrate ACP participates in the reaction [31]. The time
course of the two reactions cannot be expected to be the same.
The cerulenin complexes reveal that KAS II residues Ile108,
Val134 and Ile138 (Gly107, Val134 and Met138 in KAS I)
constrict the acyl binding pocket in two positions, and that the
binding of cerulenin induces a reorientation of Ile108 needed
to accommodate cerulenin atoms beyond the fatty acyl C7
position, as illustrated in Fig. 3C. This rotation of Ile108 in E.
coliKAS II was invoked to explain the far greater sensitivity to
cerulenin of KAS I than KAS II [32].
Although orientation of the cerulenin Cx-end varies, su-
perimposition of the KAS I:cerulenin and KAS II:cerulenin
complexes with mtKAS discloses a KAS II-like constriction of
the acyl pocket in this enzyme just beyond the fatty acyl C7ure of KAS II from S. pneumoniae (light gray) [21]. The parts of the
red black: +, residues 67–83; , residues 98–105; c, residues 374–375.
Fig. 3. KAS acyl binding pockets. The cerulenin chains from superimposed E. coli KAS I (yellow) and KAS II (orange) complexes have been in-
cluded with potential hydrogen bonds (dotted lines) to the oxyanion hole (magenta). (A) A. thaliana mtKAS acyl binding pocket. (B) E. coli KAS I
acyl binding pocket and (C) E. coli KAS II acyl binding pocket. The black side chain illustrates the orientation of Ile108 in the native KAS II
structure. Light blue residues are from the B subunits, gray residues are from the A subunits. The sequence identity of mtKAS with E. coliKAS I and
KAS II is 38% and 50%, respectively.
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Ile180 and Leu184, and we expect cerulenin binding to mtKAS
to involve a rotation of Ile154 analogous to that observed in
KAS II (Fig. 3C). Since mtKAS is at least as sensitive to
cerulenin as E. coli KAS I [10], the deduced rotation of Ile154
does not impede cerulenin binding in this enzyme. Although
slightly less spacious, the completely hydrophobic acyl binding
pocket deﬁned by Ile154, Ile157, Ile180, Ile183, and Leu184
(Ile108, Leu111, Val134, Thr137 and Ile138 in KAS II) likely
provides an almost perfect ﬁt to the ligand with respect to
shape and polarity, and hence favors inhibitor binding. We
note that cerulenin Cx is positioned as far as possible from
Thr137 OG (Ala137 in KAS I and Ile183 in mtKAS) in the
KAS II:cerulenin Cx complex, while in the KAS I:cerulenin
complex it is oriented towards the structurally equivalent
residue.
Also the bimodal product proﬁle characterizing mtKAS, but
not E. coli KAS II, indicates that reorientation of Ile154 to
another tautomer has energetically diﬀerent consequences in
the two enzymes. Likely, no substantial energy barrier existsfor reorientation of the constricting Ile residue in KAS II,
while reorientation in the more narrow mtKAS pocket is en-
ergetically unfavorable. After Ile154 reorientation, the longer
fatty acyl substrates gain access to the wider and solvent ﬁlled
interior of the mtKAS pocket (Fig. 3A).4. Conclusion
The very hydrophobic acyl binding pocket observed in this
ﬁrst structure of a mitochondrial KAS ﬁts well with the ob-
served sensitivity of the enzyme to the inhibitor cerulenin. The
orientation of Ile154 in the constricted binding pocket suggests
that this residue plays a major role for the bimodal product
proﬁle of the enzyme and its involvement in the formation of
C8-ACP for lipoic acid production.
Acknowledgements: This work was supported by Novo Nordisk
Foundation and the Danish National Research Council. Financial
support from DANSYNC and the EU, ARI program made data
174 J.G. Olsen et al. / FEBS Letters 577 (2004) 170–174collection possible. Beam line scientists Hassan Belrhali (beam line
BM14, ESRF) and Alexander Popov (Beam line X11, DESY) are
acknowledged for technical assistance during data collection and Drs.
R. Yasuno and G. Besra are thanked for the pKK233D20mtKAS clone
and the C41(DE3) cells, respectively.References
[1] Smith, S. (1994) FASEB J. 8, 1248–1259.
[2] Rock, C.O. and Cronan, J.E. (1996) Biochim. Biophys. Acta 1302,
1–16.
[3] Harwood, J.L. (1988) Ann. Rev. Plant Physiol. Plant Mol. Biol.
39, 101–138.
[4] Chuman, L. and Brody, S. (1989) Eur. J. Biochem. 184, 643–649.
[5] Shintani, D.K. and Ohlrogge, J.B. (1994) Plant Physiol. 104,
1221–1229.
[6] Torkko, J.M., Koivuranta, K.T., Miinalainen, I.J., Yagi, A.I.,
Schmitz, W., Kastaniotis, A.J., Airenne, T.T., Gurvitz, A. and
Hiltunen, K.J. (2001) Mol. Cell Biol. 21, 6243–6253.
[7] Miinalainen, I.J., Chen, Z.-J., Torkko, J.M., Pirila, P.L., Sorm-
unen, R.T., Bergmann, U., Qin, Y.-M. and Hiltunen, J.K. (2003)
J. Biol. Chem. 278, 20154–20161.
[8] Torkko, J.M., Koivuranta, K.T., Kastaniotis, A.J., Airenne, T.T.,
Glumoﬀ, T., Ilves, M., Hartig, A., Gurvitz, A. and Hiltunen, J.K.
(2003) J. Biol. Chem. 278, 41213–41220.
[9] Zhang, L., Joshi, A.K. and Smith, S. (2003) J. Biol. Chem. 278,
40067–40074.
[10] Yasuno, R., von Wettstein-Knowles, P. and Wada, H. (2004) J.
Biol. Chem. 279, 8242–8251.
[11] Pﬂug, B.R., Pecher, S.M., Brink, A.W., Nelson, J.B. and Foster,
B.A. (2003) Prostate 57, 245–254.
[12] Li, J.N., Gorospe, M., Chrest, F.J., Kumaravel, T.S., Evans,
M.K., Han, W.F. and Pizer, E.S. (2001) Cancer Res. 61, 1493–
1499.
[13] Phillips, O.A. and Matowe, W.C. (2002) Curr. Opin. Investig.
Drugs 3, 1701–1711.
[14] Moche, A., Schneider, G., Edwards, P., Dehesh, K. and Lindqvist,
Y. (1999) J. Biol. Chem. 274, 6031–6034.[15] Price, A.C., Choi, K.-H., Heath, R.J., Li, Z., White, S.W. and
Rock, C.O. (2001) J. Biol. Chem. 276, 6551–6559.
[16] Garwin, J.L., Klages, A.L. and Cronan, J.E. (1980) J. Biol. Chem.
255, 11949–11956.
[17] Gueguen, V., Macherel, D., Jaquinod, M., Douce, R. and
Bourguignon, J. (2000) J. Biol. Chem. 275, 5016–5025.
[18] Schneider, R., Brors, B., Burger, F., Camrath, S. and Weiss, H.
(1997) Curr. Genet. 32, 384–388.
[19] Olsen, J.G., Kadziola, A., von Wettstein-Knowles, P., Siggaard-
Andersen, M. and Larsen, S. (2001) Structure 9, 233–243.
[20] Huang, W., Jia, J., Edwards, P., Dehesh, K., Schneider, G. and
Lindqvist, Y. (1998) EMBO J. 17, 1183–1191.
[21] Price, A.C., Rock, C.O. and White, S.W. (2003) J. Bacteriol. 185,
4136–4143.
[22] Moche, M., Dehesh, K., Edwards, P. and Lindqvist, Y. (2001) J.
Mol. Biol. 305, 491–503.
[23] McGuire, K.A., Siggaard-Andersen, M., Bangera, M.G., Olsen,
J.G. and von Wettstein-Knowles, P. (2001) Biochemistry 40,
9836–9845.
[24] Olsen, J.G., Kadziola, A., von Wettstein-Knowles, P., Siggaard-
Andersen, M., Lindquist, Y. and Larsen, S. (1999) FEBS Lett.
460, 46–52.
[25] Navaza, J. and Saludjian, P. (1997) Meth. Enzymol. 276, 581–594.
[26] Morris, R.J., Perrakis, A. and Lamzin, V.S. (2003) Meth.
Enzymol. 374, 229–244.
[27] Jones, A., Zou, J.Y., Cowan, S.W. and Kjeldgaard, M. (1991)
Acta Crystallogr. A 47, 110–119.
[28] Br€unger, A.T., Adams, P.D., Clore, G.M., DeLano, W.L., Gros,
P., Grosse-Kunstleve, R.W., Jiang, J.-S., Kuszewski, J., Nilges,
M., Pannu, N.S., Read, R.J., Rice, L.M., Simonson, T. and
Warren, G.L. (1998) Acta Crystallogr. D 54, 905–921.
[29] Harding, M.M. (2002) Acta Crystallogr. D 58, 872–874.
[30] Hubbard, S.J. and Thornton, J.M. (1999) NACCESS. Depart-
ment of Biochemistry and Molecular Biology, University College,
London.
[31] D’Agnolo, G., Rosenfeld, I.S. and Vagelos, P.R. (1975) J. Biol.
Chem. 250, 5283–5288.
[32] Val, D., Banu, G., Seshadri, K., Lindqvist, Y. and Dehesh, K.
(2000) Structure 8, 565–566.
